Intimation of the proceedings of the 78th Annual General Meeting of Novartis India Limited held on September 24, 2026.

Novartis India Limited September 24, 2026 The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500672 Sub.: Proceedings of the 7 8th Annual General Meeting (“AGM”) of Novartis India Limited (“the Company”) held on Thursday, September 24 , 2026 Dear Sir/ Madam, The 78th Annual General Meeting (‘AGM’) of the Company was held on Thursday, September 24, 202 6, at 11:00 A.M. (IST) through Video Conferencing (‘VC’) / Other Audio -Visual Means (‘OAVM’) in accordance with the Circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. In terms of Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, the Company had provided the facility for remote e -voting to the shareholders which commenced from 9.00 A.M. (IST) on Monday, September 21 , 202 6, and ended at 5.00 P.M. (IST) on Wednesday, Septembe r 23, 202 6. Shareholders who had not cast their votes during the remote e -voting period were provided an opportunity to vote during the AGM. Pursuant to Regulation 30 (refer Para A of Part A of Schedule III) of SEBI Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025 -CFD -POD2/I/3762/2026 dated January 30, 2026 , the proceedings of AGM are as follows: A. Proceedings in brief: - 1) Ms. Chandni Maru, Company Secretary and Compliance Officer welcomed the Members to the AGM and briefed them on certain points relating to the participation at the AGM through 2) Mr. Ramesh Ramadurai , Chairperson of the Board, chaired the AGM. 3) The AGM was attended by all the Independent Directors, Managing Director & Chief Executive Officer, Non-Executive Directors, Company Secretary & Compliance Officer, Statutory Auditor, Secretarial Auditor and Scrutinizer of the Company. Registered Office: Inspire BKC, 7th Floor, Bandra -Kurla Complex, Bandra (East) , Mumbai - 400051, Maharashtra, India . CIN: L24200MH1947PLC006104 | T el: +91 22 50243000 Email: investor.relations@nilpharma.co .in | W ebsite: www.nilpharma.co.in Novartis India Limited The details of Directors attending the meeting are as follows: - Sr No. Name of Directors Designation 1. Mr. Ramesh Ramadurai Chairperson of the Board and Independent Director and member of the Audit Committee, Nomination and Remuneration Committee, and Corporate Social Responsibility Committee of the Company . 2. Ms. Suchita Sharma Independent Director and Chairperson of the Audit Committee and a member of the Stakeholders' Relationship Committee and Corporate Social Responsibility Committee 3. Mr. Shashank Sinha Independent Director and Chairperson of the Risk Management Committee and the Nomination and Remuneration Committee and is a member of the Audit Committee 4. Dr. Vikas Gupta Managing Director and Chief Executive Officer of the Company and member of the Risk Management Committee and the Stakeholders' Relationship Committee 5. Mr. Ashok Bhatia Non-Executive Director and Chairperson of the Stakeholders' Relationship Committee and Corporate Social Responsibility Committee and member of the Risk Management Committee 6. Mr. Kshitij Pankaj Sheth Non-Executive Director and member of the Nomination and Remuneration Committee. 7. Dr. Jagriti Gupta Non-Executive Director and member of the Audit Committee. 4) The required quorum was present throughout the Meeting. 5) With the consent of the Members, the Notice along with the Corrigendum convening the 7 8th AGM, having been circulated to all the members and was taken as read. 6) The Chairperson introduced each Director present at the meeting. Registered Office: Inspire BKC, 7th Floor, Bandra -Kurla Complex, Bandra (East) , Mumbai - 400051, Maharashtra, India . CIN: L24200MH1947PLC006104 | T el: +91 22 50243000 Email: investor.relations@nilpharma.co .in | W ebsite: www.nilpharma.co.in Novartis India Limited 7) The Chairperson confirmed that there were no qualifications, adverse remarks, observations or comments in the Independent Auditor’s Report. 8) Mr. Ramesh Ramadurai, the Chairperson, delivered his speech followed by Dr. Vikas Gupta , Managing Directo r and Chief Executive Officer who also delivered his speech at the meeting. 9) The shareholders were informed that the results of the e -voting along with the Scrutinizer’s Report shall be submitted to the Stock Exchange and the same shall be placed on the website of the Company. 10) Ms. Chandni Maru, Company Secretary and Compliance Officer , informed the Members about the 16 Ordinary and Special Business Items proposed for approval by Members at the Meeting. 11 ) The following items, forming part of the Notice for the said AGM, were transacted by the shareholders through remote e -Voting (during e -Voting period and at the AGM held today) . Ordinary Business: 1. Consideration and adoption of the Audited Balance Sheet as on March 31, 2026 , and the Statement of Profit and Loss for the Financial Year ended March 31, 2026, together with the Reports of the Board of Directors and the Auditors thereon . Special Business: 2. Regularization of the appointment of Mr. Ashok Bhatia (DIN: 02090239), Additional Non - Executive Director, by appointing him as a Non -Executive Director of the Company. 3. Regularization of the appointment of Mr. Kshitij Sheth (DIN: 00125058) Additional Non - Executive Director, by appointing him as a Non -Executive Director of the Company. 4. Regularization of the appointment of Dr. Jagriti Gupta (DIN: 11760159) Additional Non - Executive Director, by appointing her as a Non -Executive Director of the Company. 5. Regularization of the appointment of Mr. Ramesh Ramadurai (DIN: 07109252), Additional Director (Independent Category), by appointing him as an Independent Director of the Company. 6. Regularization of the appointment of Mr. Shashank Sinha (DIN: 02544431), Additional Director (Independent Category), by appointing him as an Independent Director of the Company. 7. Regularization of the appointment of Ms. Suchita Sharma (DIN: 10656028), Additional Director (Independent Category), by appointing her as an Independent Director of the Company. 8. Regularization of the appointment of Dr. Vikas Gupta (DIN: 10704329), Additional Director (Executive Category), by appointing him as a Director of the Company, liable to retire by rotation. 9. Approval of the Employee Stock Option Scheme 2026 (“ESOP 2026”) Registered Office: Inspire BKC, 7th Floor, Bandra -Kurla Complex, Bandra (East) , Mumbai - 400051, Maharashtra, India . CIN: L24200MH1947PLC006104 | T el: +91 22 50243000 Email: investor.relations@nilpharma.co .in | W ebsite: www.nilpharma.co.in Novartis India Limited 10. Approval of the appointment of Dr. Vikas Gupta (DIN: 10704329) as Managing Director and Chief Executive Officer of the Company and approval of his remuneration. 11 . Approval of the adoption of the altered Memorandum of Association of the Company in accordance with the provisions of the Companies Act, 2013. 12. Approval of the adoption of the altered Articles of Association of the Company in accordance with the provisions of the Companies Act, 2013. 13. Approval of the change of name of the Company and the consequential alteration of the Memorandum of Association and Articles of Association of the Company. 14. Ratification of the remuneration payable to M/s. D. C. Dave & Co., Cost Accountants (Firm Registration No. 000611), appointed as the Cost Auditors of the Company pursuant to Section 148 of the Companies Act, 2013 and the rules made thereunder. 15. Approval of the payment of Commission (including sitting fees) to Independent Directors of the Company. 16. Approval of the Payment of remuneration to Mr. Ashok Bhatia, Non -Executive Director. 12) The Chairperson then invited the members who had registered in advance with the Company to express their views, seek clarifications, and raise queri [Showing first 8,000 characters — download PDF for full document]